166 related articles for article (PubMed ID: 28437722)
41. The ovine nasal mucosa: an alternative tissue site for mucosal immunization.
Sedgmen BJ; Lofthouse SA; Meeusen EN
Methods; 2006 Feb; 38(2):112-6. PubMed ID: 16427306
[TBL] [Abstract][Full Text] [Related]
42. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of NR2B peptide as subunit vaccines against experimental neuropathic pain.
Wang GM; Tian YK; Chen JP; Tian XB; Gao F; Yang H; An K; Ma GP
Chin Med J (Engl); 2007 Apr; 120(8):643-7. PubMed ID: 17517177
[TBL] [Abstract][Full Text] [Related]
44. Characterization of the adaptive immune response following immunization in pregnant sows (Sus scrofa) kept in two different housing systems.
Grün V; Schmucker S; Schalk C; Flauger B; Stefanski V
J Anim Sci; 2014 Aug; 92(8):3388-97. PubMed ID: 24948651
[TBL] [Abstract][Full Text] [Related]
45. Long-lasting humoral immune response induced in HIV-1-infected patients by a synthetic peptide (AT20) derived from the HIV-1 matrix protein p17 functional epitope.
Focà E; Iaria ML; Caccuri F; Fiorentini S; Motta D; Giagulli C; Castelli F; Caruso A
HIV Clin Trials; 2015 Aug; 16(4):157-62. PubMed ID: 26057863
[TBL] [Abstract][Full Text] [Related]
46. Active immunization alters the plasma nicotine concentration in rats.
Hieda Y; Keyler DE; Vandevoort JT; Kane JK; Ross CA; Raphael DE; Niedbalas RS; Pentel PR
J Pharmacol Exp Ther; 1997 Dec; 283(3):1076-81. PubMed ID: 9399979
[TBL] [Abstract][Full Text] [Related]
47. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.
Heimberger AB; Crotty LE; Archer GE; Hess KR; Wikstrand CJ; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Clin Cancer Res; 2003 Sep; 9(11):4247-54. PubMed ID: 14519652
[TBL] [Abstract][Full Text] [Related]
48. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
Helling F; Zhang S; Shang A; Adluri S; Calves M; Koganty R; Longenecker BM; Yao TJ; Oettgen HF; Livingston PO
Cancer Res; 1995 Jul; 55(13):2783-8. PubMed ID: 7796403
[TBL] [Abstract][Full Text] [Related]
49. Stressor exposure produces long-term reductions in antigen-specific T and B cell responses.
Gazda LS; Smith T; Watkins LR; Maier SF; Fleshner M
Stress; 2003 Dec; 6(4):259-67. PubMed ID: 14660058
[TBL] [Abstract][Full Text] [Related]
50. Prophylactic active immunization with a novel epitope vaccine improves cognitive ability by decreasing amyloid plaques and neuroinflammation in APP/PS1 transgenic mice.
Ding L; Meng Y; Zhang HY; Yin WC; Yan Y; Cao YP
Neurosci Res; 2017 Jun; 119():7-14. PubMed ID: 28111220
[TBL] [Abstract][Full Text] [Related]
51. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao TJ; Panageas K; Moynahan M; Houghton A; Norton L; Livingston PO
Clin Cancer Res; 2000 May; 6(5):1693-701. PubMed ID: 10815887
[TBL] [Abstract][Full Text] [Related]
52. Distribution of methamphetamine and its metabolite amphetamine in acute and subacute ethanol-methamphetamine combination abuse model rats.
Liang M; Liu Y; Zheng N; Ananda S; Liu L
J Anal Toxicol; 2012; 36(1):30-5. PubMed ID: 22290750
[TBL] [Abstract][Full Text] [Related]
53. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.
Schmittling RJ; Archer GE; Mitchell DA; Heimberger A; Pegram C; Herndon JE; Friedman HS; Bigner DD; Sampson JH
J Immunol Methods; 2008 Nov; 339(1):74-81. PubMed ID: 18775433
[TBL] [Abstract][Full Text] [Related]
54. A potential vaccine for cocaine abuse prophylaxis.
Bagasra O; Forman LJ; Howeedy A; Whittle P
Immunopharmacology; 1992; 23(3):173-9. PubMed ID: 1500284
[TBL] [Abstract][Full Text] [Related]
55. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies.
Yao TJ; Meyers M; Livingston PO; Houghton AN; Chapman PB
Clin Cancer Res; 1999 Jan; 5(1):77-81. PubMed ID: 9918205
[TBL] [Abstract][Full Text] [Related]
56. Vaccine development against methamphetamine drug addiction.
Hossain MK; Hassanzadeganroudsari M; Nurgali K; Apostolopoulos V
Expert Rev Vaccines; 2020 Dec; 19(12):1105-1114. PubMed ID: 33251859
[TBL] [Abstract][Full Text] [Related]
57. Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.
Kataoka K; Fukuyama Y; Briles DE; Miyake T; Fujihashi K
Microbiol Immunol; 2017 Jun; 61(6):195-205. PubMed ID: 28463465
[TBL] [Abstract][Full Text] [Related]
58. Determination of the effect of calcineurin inhibitors on the rat's immune system after KLH immunisation.
Roman D; Ulrich P; Paul G; Court M; Vit P; Kehren J; Mahl A
Toxicol Lett; 2004 Apr; 149(1-3):133-40. PubMed ID: 15093258
[TBL] [Abstract][Full Text] [Related]
59. RU-486 blocks differentially suppressive effect of stress on in vivo anti-KLH immunoglobulin response.
Fleshner M; Brennan FX; Nguyen K; Watkins LR; Maier SF
Am J Physiol; 1996 Nov; 271(5 Pt 2):R1344-52. PubMed ID: 8945973
[TBL] [Abstract][Full Text] [Related]
60. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
Bingham CO; Looney RJ; Deodhar A; Halsey N; Greenwald M; Codding C; Trzaskoma B; Martin F; Agarwal S; Kelman A
Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
